D-0141-2024 Class II
FDA drug recall D-0141-2024 was initiated by Wells Pharma Of Houston LLC on Nov 22, 2023 and is designated Class II. Reason for recall: Lack of assurance of sterility. Affected quantity: 825 syringes.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 13, 2023
- Initiation Date
- Nov 22, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 825 syringes
Product description
ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10
Reason for recall
Lack of assurance of sterility.
Distribution pattern
Philadelphia, Pennsylvania.
Code information
Lot # 11092313110#01, Exp 01/12/24
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0141-2024
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026